Idorsia aims to be Europe’s leading biopharmaceutical company, with a strong scientific core. We provide regular updates on the progress being made towards this goal. This section of the website provides journalists with additional material to support the generation of articles.
News
07 Feb 2023 | |
06 Feb 2023 | |
09 Jan 2023 |
Events
Event | When |
Credit Suisse London Healthcare Conference
|
February 28 - March 1, 2023 |
Barclay's Healthcare Conference
|
March 14-15, 2023 |
Jefferies 3rd Pan European Mid Cap Conference
|
March 28-30, 2023 |
First Quarter 2023 Financial Results reporting*
|
April 25, 2023 |
Annual General Meeting of Shareholders |
May 4, 2023 |
Bank of America Healthcare Conference |
May 9-11, 2023 |
Jefferies Healthcare Conference |
June 7-9, 2023 |
Goldman Sachs Global Healthcare Conference |
June 12-15, 2023 |
Citi European Healthcare Conference |
June 20-21, 2023 |
J.P. Morgan European Healthcare Conference |
June 22, 2023 |
Stifel European Healthcare Summit |
June 29-30, 2023 |
Half-Year 2023 Financial Results reporting* |
July 25, 2023 |
Citi BioPharma Conference |
September 6-7, 2023 |
Morgan Stanley Global Healthcare Conference |
September 11-14, 2023 |
Bank of America Global Healthcare Conference |
September 13-14, 2023 |
Baader Investment Conference |
September 18-22, 2023 |
9-month 2023 Financial Results reporting* |
October 24, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Stay informed
Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.
Social Media
Idorsia is active on social media – follow our channels to get a more personal view on the company.
Media center
Idorsia provides images, fact sheets and B-roll to download or support you with your article.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications
Media Relations
Resources in German
Als schweizerisches Unternehmen stellen wir interessierten Personen auf dieser Seite wesentliche Informationen über unser Unternehmen in deutscher Sprache zur Verfügung.